Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy

Table 1 Patient background data

	Short-term usagegroup (n = 91)		Long-term usageGroup (n = 83)
	Median	Range	Median	Range
Age at cessation (yr)	69	54-78	73	53-90
Body mass index	24.1	18.6-32.5	24.3	17.1-32.5
Duration of GnRHa (mo)	6	3-12	47	36-66
Follow-up duration from cessation of GnRHa (mo)	29	3-52	60	3-94
	n	%	n	%
Diabetes, yes	10	10.9	8	9.6
Hypertension, yes	36	39.5	33	39.7

GnRHa: Gonadotropin-releasing hormone agonist therapy.

Table 2 Univariate and multivariate analyses of factors associated with testosterone recovery to supracastrate levels in the long-term usage group

Factor	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
At brachytherapy
Body mass index
< 25	1.249	0.733-2.130	0.413	-	-	-
≥ 25	1.000	(reference)		-	-	-
Diabetes
No	1.262	0.505-3.156	0.687	-	-	-
Yes	1.000	(reference)		-	-	-
Hypertension
No	0.959	0.572-1.608	0.873	-	-	-
Yes	1.000	(reference)		-	-	-
At cessation
Age
< 73 yr	1.98	1.182-3.317	0.009	2.020	1.190-3.429	0.009
≥ 73 yr	1.000	(reference)		1.000	(reference)
T level at baseline1
< 10 ng/dL	1.000	(reference)		1.000	(reference)
≥ 10 ng/dL	2.261	1.316-3.883	0.003	2.327	1.354-4.000	0.002
Drug formulation
Duration of activity
1 mo	1.000	(reference)		-	-	-
3 mo	1.419	0.821-2.454	0.209	-	-	-
Material
Goserelin	0.973	0.579-1.635	0.917	-	-	-
Leuprorelin	1.000	(reference)		-	-	-

¹Testosterone level at baseline was measured 1 mo before the cessation of androgen deprivation therapy. Statistical significance was assessed at P < 0.05. T: Testosterone.